pd

Documents about pd

• A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer#803057ClinicalTrials.gov
• 5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors#862480ClinicalTrials.gov
• PD-1/PD-L1 in Myocarditis Transcriptional Signals, Functional Questions#675875eScholarship
• Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists#842712ClinicalTrials.gov
• PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer#6810OpenAlex
• Anti-PD-1/PD-L1 Antibodies Plus Gemcitabine and Cisplatin for Advanced CCA#474744ClinicalTrials.gov
• Percept Transitions in FOG and PD#805779ClinicalTrials.gov
• Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001)#877826ClinicalTrials.gov
• Study of CDK4/6 Inhibitor Combined With PD-L1 Monoclonal Antibody in the Treatment of PD-1/PD-L1 Resistance and Abnormal Cell Cycle Digestive System Tumors#346940ClinicalTrials.gov
• Safety and Efficacy of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Selected Advanced Solid Tumors#859401ClinicalTrials.gov
• Heterogeneity of macrophages in PD-1/PD-L1 inhibitor therapy: a single-cell perspective.#288709NCBI PubMed Central
• Peripheral blood biomarkers in PD-1/PD-L1 immunotherapy: distinguishing predictive from prognostic biomarkers.#685559NCBI PubMed Central
• Understanding Teacher PD in the Greater Newark STEM Ecosystem: What Do Educators Need, and How Can We Deliver It?#168742Digital Commons @ NJIT
• Inetetamab Plus Chemotherapy ± PD-1/PD-L1 in HER2+ Advanced Biliary Cancer#683095ClinicalTrials.gov
• QL1706 in Patients With Recurrent and Metastatic Cervical Cancer Resistant to Prior PD-1/PD-L1 Antibody Therapy#872863ClinicalTrials.gov
• Angiogenesis Inhibitor Plus Anti-PD-1/PD-L1 Antibody in Advanced Esophageal Cancer#803694ClinicalTrials.gov
• DEP Combine With PD-1 Antibody as an Treatment for EBV-HLH#811308ClinicalTrials.gov
• Controlled Cold Exposure Combined With PD-1/PD-L1 Immunotherapy in Solid Tumors (NIVALIS)#272361ClinicalTrials.gov
• Pd-1 Antibody Combined CCRT for Local Advanced Cervical Cancer.#838903ClinicalTrials.gov
• SBRT + PD-1/PDL-1 Inhibiting Therapy for Advanced Solid Tumors After Dz Control on PD-1/PDL-1 Tx#329502ClinicalTrials.gov
• Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Anti-PD-1/PD-L1 Therapy in Patients With Solid Tumors#390947ClinicalTrials.gov
• Küçük hücreli dışı akciğer kanserlerinde immunhistokimyasal CMTM6 ve PD-L1 'in klinikopatolojik ve prognostik önemi#442829Necmettin Erbakan University Institutional Repository
• Consortium On Risk for Early-onset Parkinson's Disease (CORE PD)#813529ClinicalTrials.gov
• Adaptive DBS for PD#843318ClinicalTrials.gov
• Coorticosteroid Regimen in Patients With Anti-PD-1/PD-L1 Induced Pneumonitis#201775ClinicalTrials.gov
• PD-1 Antibody Combined Neoadjuvant Chemotherapy for Ovarian Cancer#253000ClinicalTrials.gov
• Anti PD-1 Plus Postbiotic Versus Anti PD-1 Alone in Locally Advanced or Metastatic, Treatment naïve, Cutaneous Melanoma Study#467571ClinicalTrials.gov
• PD-1 Antibody Adjuvant Therapy for GC Patients With MSI-H After D2 Radical Surgery#467585ClinicalTrials.gov
• Evaluate the Safety and Feasibility of Injecting PMD-MSC Into the Penis to Treat the Symptoms of PD#861819ClinicalTrials.gov
• Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors#180214ClinicalTrials.gov
• First-line Treatment for ES-SCLC with Chemotherapy Combined with PD-1/PD-L1 Inhibitor Sequential Thoracic Radiotherapy#184846ClinicalTrials.gov
• Light-enhanced cytotoxicity and intracellular trafficking of the PD-L1-targeting photoimmunoconjugate EITC-atezolizumab#185444IRIS
• SHR0302 Combined With PD-1/PD-L1 Inhibition for Treatment naïve or Acquired Resistant to Immunology NSCLC#245495ClinicalTrials.gov
• Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC#807994ClinicalTrials.gov
• Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic Cancer#853122ClinicalTrials.gov
• Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite Stable Metastatic Colorectal Cancer#863119ClinicalTrials.gov
• FH-006 Versus Investigator's Choice of Chemotherapy in Patients With Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma Who Have Failed Prior PD-1/PD-L1 Inhibitor Combined With Platinum-Based Chemotherapy.#836487ClinicalTrials.gov
• Analyzing the polytwin microstructure in L10+L12 Fe–Pd alloys: Theory and experiment#272651Digital Commons @ Michigan Tech
• QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy#332756ClinicalTrials.gov
• Electroacupuncture Combined With PD-1 Inhibitor for Elderly Patients With Advanced NSCLC#366609ClinicalTrials.gov
• SEC 8-K — SCHWAB CHARLES CORP (SCHW, SCHW-PD, SCHW-PJ) (0001193125-20-150725) · filed 2020-05-26#608771SEC EDGAR
• Total Neoadjuvant Treatment Plus PD-1 in Mid-Low Locally Advanced Rectal Cancer#28328ClinicalTrials.gov
• LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study#226236ClinicalTrials.gov
• Assessment of Safety and Efficacy of OPM-101 Combined With Anti-PD-1 in Patients With Advanced Melanoma Showing Resistance to Anti-PD-1#321699ClinicalTrials.gov
• Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of Nasopharyngeal Carcinoma#442093ClinicalTrials.gov
• PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC#813422ClinicalTrials.gov
• L-TIL in Patients With Malignancy Resistance to Anti-PD-1 Therapy#824792ClinicalTrials.gov
• Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven Criteria#856595ClinicalTrials.gov
• PD-1 Blockade With JS001 Plus Neoadjuvant Chemotherapy for Gastric/Gastroesophageal Junction Cancer#860077ClinicalTrials.gov
• Chinese PD Registry#387244ClinicalTrials.gov

Related topics